Advances in Antibody–Drug Conjugate Conjugation: Methods, Challenges, and Improvements
-- Addressing Conjugation Instability and Site-Specificity in ADC Design
DOI:
https://doi.org/10.54097/dze05379Keywords:
Antibody-drug Conjugates, ADCs, Antitumour Agents, Bioconjugation, Site-Specific Modification, Therapeutic Activity, OptimisationAbstract
Antibody-drug conjugates (ADCs) are targeted biopharmaceuticals that constitutes monoclonal antibody selectivity with the cytotoxic strength of small-molecule drugs. Over the past decades, a growing number of reagents and studies have been proposed, and substantial progress has been achieved in improving conjugate homogeneity, linker chemistry, and payload design. One of the typical conjugation methods, maleimide-thiol conjugation, has been proposed in the first-generation ADCs, and the problems related to retro-Michael conjugation have been tackled by the study of succinimide ring hydrolysis. Apart from that, a wide range of reagents and new linkers for disulfide bond re-bridging have been studied as well. This mini-review summarises these core strategies, critically examining their mechanistic principles, limitations, and recent innovations that collectively shape the evolution of next-generation ADC design.
Downloads
References
[1] Hamilton G. S. (2015). Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids. Biologicals, 43(5), 318–332. DOI 10.1016/j. biologicals. 2015. 05.006.
[2] Fu Z., Li S., Han S., Shi C., & Zhang Y. (2022). Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(1), 93. DOI 10.1038/s41392-022-00947-7.
[3] Walsh S. J., Bargh J. D., Dannheim F. M., Hanby A. R., Seki H., Counsell A. J., Ou X., Fowler E., Ashman N., Takada Y., Isidro-Llobet A., Parker J. S., Carroll J. S., & Spring D. R. (2021). Site-selective modification strategies in antibody–drug conjugates. Chemical Society Reviews, 50(2), 1305–1353. DOI 10.1039/D0CS00310G.
[4] Beckley N. S., Lazzareschi K. P., Chih H.-W., Sharma V. K., & Flores H. L. (2013). Investigation into Temperature-Induced Aggregation of an Antibody Drug Conjugate. Bioconjugate Chemistry, 24(10), 1674–1683. DOI 10.1021/bc400182x.
[5] Adem Y. T., Schwarz K. A., Duenas E., Patapoff T. W., Galush W. J., & Esue O. (2014). Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload. Bioconjugate Chemistry, 25(4), 656–664. DOI 10. 1021/ bc 400439x.
[6] Beck A., Goetsch L., Dumontet C., & Corvaïa N. (2017). Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery, 16(5), 315–337. DOI 10.1038/nrd.2016.268.
[7] Szijj P. A., Bahou C., & Chudasama V. (2018). Minireview: Addressing the retro-Michael instability of maleimide bioconjugates. Drug Discovery Today: Technologies, 30, 27–34. DOI 10.1016/j. ddtec. 2018.07.002.
[8] Shen B.-Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., Parsons-Reponte K. L., Tien J., Yu S.-F., Mai E., Li D., Tibbitts J., Baudys J., Saad O. M., Scales S. J., McDonald P. J., Hass P. E., Eigenbrot C., Nguyen T., … Junutula J. R. (2012). Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature Biotechnology, 30 (2), 184–189. DOI 10.1038/nbt.2108.
[9] Alley S. C., Benjamin D. R., Jeffrey S. C., Okeley N. M., Meyer D. L., Sanderson R. J., & Senter P. D. (2008). Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates. Bioconjugate Chemistry, 19(3), 759–765. DOI 10.1021/bc7004329.
[10] Tumey L. N., Charati M., He T., Sousa E., Ma D., Han X., Clark T., Casavant J., Loganzo F., Barletta F., Lucas J., & Graziani E. I. (2014). Mild Method for Succinimide Hydrolysis on ADCs: Impact on ADC Potency, Stability, Exposure, and Efficacy. Bioconjugate Chemistry, 25(10), 1871–1880. DOI 10.1021/ bc500357n.
[11] Lyon R. P., Setter J. R., Bovee T. D., Doronina S. O., Hunter J. H., Anderson M. E., Balasubramanian C. L., Duniho S. M., Leiske C. I., Li F., & Senter P. D. (2014). Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nature Biotechnology, 32(10), 1059–1062. DOI 10.1038/nbt.2968.
[12] Fontaine S. D., Reid R., Robinson L., Ashley G. W., & Santi D. V. (2015). Long-Term Stabilization of Maleimide–Thiol Conjugates. Bioconjugate Chemistry, 26(1), 145–152. DOI 10.1021/bc5005262.
[13] Christie R. J., Fleming R., Bezabeh B., Woods R., Mao S., Harper J., Joseph A., Wang Q., Xu Z.-Q., Wu H., Gao C., & Dimasi N. (2015). Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides Journal of controlled release: official journal of the Controlled Release Society, 220(Pt B), 660–670. DOI 10.1016/j.jconrel.2015.09.032.
[14] Forte N., Chudasama V., & Baker J. R. (2018). Homogeneous antibody-drug conjugates via site-selective disulfide bridging. Drug Discovery Today: Technologies, 30, 11–20. DOI 10. 1016/ j.ddtec.2018.09.004.
[15] Shaunak S., Godwin A., Choi J.-W., Balan S., Pedone E., Vijayarangam D., Heidelberger S., Teo I., Zloh M., & Brocchini S. (2006). Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nature Chemical Biology, 2(6), 312–313. DOI 10.1038/nchembio786.
[16] Pfisterer A., Eisele Dr. K., Chen X., Wagner Dr. M., Müllen Prof. Dr. K., & Weil Prof. Dr. T. (2011, July 11). Bioactive Unnatural Somatostatin Analogues through Bioorthogonal Iodo- and Ethynyl-Disulfide Intercalators. Chemistry (Weinheim an der Bergstrasse, Germany), 17(35), 9697–9707. DOI 10.1002/chem.201100287.
[17] Badescu G., Bryant P., Bird M., Henseleit K., Swierkosz J., Parekh V., Tommasi R., Pawlisz E., Jurlewicz K., Farys M., Camper N., Sheng X., Fisher M., Grygorash R., Kyle A., Abhilash A., Frigerio M., Edwards J., & Godwin A. (2014). Bridging Disulfides for Stable and Defined Antibody Drug Conjugates. Bioconjugate Chemistry, 25(6), 1124–1136. DOI 10.1021/bc500148x.
[18] King T. A., Walsh S. J., Kapun M., Wharton T., Krajcovicova S., Glossop M. S., & Spring D. R. (2023). Disulfide re-bridging reagents for single-payload antibody-drug conjugates. Chemical Communications, 59(65), 9868–9871. DOI 10.1039/ D3CC02980H.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
